Advertisement

Topics

PubMed Journals Articles About "Appraising Risk Active Surveillance Localized Prostate Cancer" RSS

12:04 EDT 25th June 2019 | BioPortfolio

Appraising Risk Active Surveillance Localized Prostate Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Appraising Risk Active Surveillance Localized Prostate Cancer articles that have been published worldwide.

More Information about "Appraising Risk Active Surveillance Localized Prostate Cancer" on BioPortfolio

We have published hundreds of Appraising Risk Active Surveillance Localized Prostate Cancer news stories on BioPortfolio along with dozens of Appraising Risk Active Surveillance Localized Prostate Cancer Clinical Trials and PubMed Articles about Appraising Risk Active Surveillance Localized Prostate Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Appraising Risk Active Surveillance Localized Prostate Cancer Companies in our database. You can also find out about relevant Appraising Risk Active Surveillance Localized Prostate Cancer Drugs and Medications on this site too.

Showing "Appraising risk active surveillance localized prostate cancer" PubMed Articles 1–25 of 39,000+

Appraising risk in active surveillance of localized prostate cancer.

Men diagnosed with low-risk prostate cancer are typically eligible for active surveillance of their cancer, involving monitoring for cancer progression and making judgements about the risks of prostate cancer against those of active intervention. Our study examined how risk for prostate cancer is perceived and experienced by patients undergoing active surveillance with their clinicians, how risk is communicated in clinical consultations, and the implications for treatment and care.


Active surveillance of prostate cancer : An update.

Prostate cancer is a heterogeneous disease. In cases of low-risk prostate cancer, active surveillance represents an attractive alternative treatment. Significant complications of a definitive treatment can therefore be delayed or completely avoided. Despite strict inclusion criteria for active surveillance, the diagnosis of low-risk prostate cancer can be inaccurate and there is therefore a risk of missing the optimal point in time for definitive treatment. Multimodal diagnostics and continuous aftercare ...

Evidence-based approach to active surveillance of prostate cancer.

Active surveillance is a good management option for some men with non-metastatic prostate cancer. In this review, we examine the evidence for several topics related to active surveillance. We examine: (1) which patients should be eligible for active surveillance, (2) what follow-up (monitoring) protocols should be used for men on surveillance, (3) what is the role of prostate magnetic resonance imaging (MRI) for men on surveillance, and (4) what is the prognosis for men who choose surveillance compared to r...


Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.

Determining prostate cancer (PCa) aggressiveness and reclassification are critical events during the treatment of localized disease and for patients undergoing active surveillance (AS). Since T cells play major roles in cancer surveillance and elimination, we aimed to identify genetic biomarkers related to T cell cancer immune response which are predictive of aggressiveness and reclassification risks in localized PCa. The genotypes of 3,586 single nucleotide polymorphisms (SNPs) from T cell cancer immune re...

The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).

A systematic repeat biopsy is recommended for men starting on active surveillance for prostate cancer, but the optimal number and distribution of cores are unknown.

Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer.

Approximately 15% of men with newly diagnosed prostate cancer have high-risk features that increase the risk of recurrence and metastasis. Better predictive biomarkers could allow for earlier detection of biochemical recurrence (BCR) and change surveillance and adjuvant treatment paradigms. Circulating tumor cells (CTCs) are thought to represent the earliest form of metastases, however their role as biomarkers in men with high-risk localized prostate cancer (HRLPCa) is not well defined.

STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER.

Genomic testing may improve risk stratification for men with prostate cancer managed with active surveillance (AS). We aimed to characterize the stability and utility of serial genomic test scores in men undergoing serial biopsies during AS.

Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.

The adverse effects of overdiagnosis and overtreatment observed in men with clinically insignificant prostate cancers after the introduction of prostate-specific antigen-based screening are now being observed in those with thyroid cancer, owing to the introduction of new imaging technologies. Thus, the evolving paradigm of active surveillance in prostate and thyroid cancers might be valuable in informing the development of future active surveillance protocols. The lessons learned from active surveillance an...

Using prognosis to guide inclusion criteria, define standardized end-points and stratify follow up in active surveillance for prostate cancer.

To test whether using disease prognosis can inform a rational approach to Active Surveillance (AS) for early prostate cancer METHODS: We previously developed the Cambridge Prognostics Groups (CPG), a 5-tiered model that uses PSA, Grade Group and stage to predict cancer survival outcomes. We applied the CPG model to a UK and a Swedish prostate cancer cohort to test differences in prostate cancer mortality (PCM) in men managed conservatively or by upfront treatment in CPG2 and 3 (which subdivides the intermed...

Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.

Whether men with Gleason 3+4 prostate cancer are appropriate active surveillance (AS) candidates remains a matter of debate.

Cost-Effectiveness of Active Surveillance, Radical Prostatectomy, and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.

Despite increasing emphasis on value-based care, the cost-effectiveness of prostate cancer (PCa) management options has not been compared using prospective clinical trial data. The prostate testing for cancer and treatment (ProtecT) trial demonstrated no difference in survival for patients randomized to active surveillance (AS), external beam radiotherapy (RT), or radical prostatectomy (RP). Herein, we compare the cost-effectiveness among the arms of ProtecT.

Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS).

Active surveillance (AS) is increasingly used to monitor patients with low-risk prostate cancer; however, approximately 50% of AS patients experience disease reclassification requiring definitive treatment and little is known about patient characteristics that modify the risk of reclassification. Obesity may be one of the major contributing factors. The Prostate Cancer Active Lifestyle Study (PALS) is a clinical trial evaluating the impact of weight loss among overweight/obese (Body Mass Index (BMI) ≥...

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.

In daily practice, a wider range of patients with prostate cancer (PCa) are selected for active surveillance (AS) compared to those in AS trials, including higher-risk patients. However, less is known about the outcomes for off-protocol selected PCa patients who opt for AS.

Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer.

Current trends in renal transplantation such as improvement of allograft/ recipient survivals and expansion of organ transplantation eligibility criteria into older recipients are concomitant with increasingly detected low risk prostate cancer (PCa) in candidates for or recipients of renal transplantation. We review the evidence regarding PCa screening, diagnosis and management in renal transplant candidates and recipients. We focus on published reports regarding incidence and diagnosis of PCa in patients w...

Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study.

To assess the outcomes of active monitoring (active surveillance or watchful waiting) as an initial management approach compared to upfront definitive local treatments (prostatectomy or radiation therapy) in a cohort of clinically localized prostate cancer patients.

Three-year active surveillance outcomes in a contemporary community urology cohort in the United States.

To determine the 3-year outcomes of men with prostate cancer managed with active surveillance (AS) in a cohort of geographically diverse community-based urology practices. AS is the management of choice for a majority of men with lower risk prostate cancer. Little is known about the contemporary "real-world" follow-up and adherence rates in the most common setting of urologic care, community (private) practice. METHODS: We retrospectively evaluated outcomes for men diagnosed between 1/1/2013 - 5/31/2014 wit...

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.

Active surveillance (AS) of prostate cancer (PC) has increased in popularity to address overtreatment.

Prostate cancer risk by occupation in the Occupational Disease Surveillance System (ODSS) in Ontario, Canada.

Previous Canadian epidemiologic studies have identified associations between occupations and prostate cancer risk, though evidence is limited. However, there are no well-established preventable risk factors for prostate cancer, which warrants the need for further investigation into occupational factors to strengthen existing evidence. This study uses occupation and prostate cancer information from a large surveillance cohort in Ontario that linked workers' compensation claim data to administrative health da...

Best practice in Active Surveillance for men with prostate cancer: A Prostate Cancer UK consensus statement.

To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts.

A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance.

OncotypeDx Genomic Prostate Score (GPS) test is an RNA expression assay that can be performed on prostate biopsies. We sought to determine whether GPS was associated with increased risk of adverse pathology for men enrolled on active surveillance (AS) who later underwent RP.

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

For men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer. This study examined the association of urinary PCA3 and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification.

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015.

Active Surveillance for Low-Risk Prostate Cancer in Black Patients.

Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.

It has been shown that active surveillance (AS) is feasible and effective in a subset of patients with recurrent low-grade (LG) non-muscle-invasive bladder cancer (NMIBC).

The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study.

Active surveillance (AS) has limitations that include missing high-risk tumors and performing unnecessary biopsies. The use of multiparametric magnetic resonance imaging (mpMRI) in AS may overcome these limitations, but its cost-effectiveness remains uncertain.


Advertisement
Quick Search
Advertisement
Advertisement